Oncolytic adenovirus platform
The platform is designed for intravenous, intravitreal, and antitumoral delivery.
Source: LinkedIn company description · Retrieved October 13, 2026
Theriva Biologics is a clinical-stage company developing therapeutics for diseases with high unmet need.
The company entered oncology through the acquisition of VCN Biosciences, which developed an oncolytic adenovirus platform.
Based on the company’s public LinkedIn information, supplied through RevenueBase.
The platform is designed for intravenous, intravitreal, and antitumoral delivery.
Source: LinkedIn company description · Retrieved October 13, 2026
Its lead candidate VCN-01 is designed to replicate selectively in tumor cells and degrade the tumor stroma barrier.
Source: LinkedIn company description · Retrieved October 13, 2026
Supported appearances on published RevenueBase lists, including available memberships beyond displayed rankings.
Positions describe ordering within each source list. See how lists are built ↗
Embeddable award for your website
RevenueBase prepared this profile from the company’s public LinkedIn information and RevenueBase company data. These source records were retrieved on October 13, 2026. AI helped summarize these sources, with a separate automated check against the source text completed on November 4, 2026. Directory positions use company-contact counts from separate saved list snapshots dated September 14, 2026, September 15, 2026, September 18, 2026 and October 7, 2026. How the company lists are built.
Share a correction, your relationship to the company, and supporting sources. Requests are reviewed before changes are published.
Explore more companies by name, headquarters and business focus.